Sep 2026· Canadian Journal of Health Technologies· Vol 6· 0 citations
TL;DR
There may be opportunities for future alignment of oncology medication funding policies across public drug plans in Canada, including alignment of definitions for hospital-administered, take-home, and supportive care.
Abstract
What Is the Issue?
Oncology medications can be broadly classified into treatments that are administered in a hospital and treatments that can be taken in the home setting.
In Canada, public drug plan reimbursement for oncology medication varies between federal, provincial, and territorial (FPT) jurisdictions, and depending on the setting of administration.
What Did We Do?
We conducted a literature search of key resources, including the websites of health care agencies in Canada and FPT public drug programs as well as a focused internet search. This information was validated and supplemented with details gathered from surveying FPT public drug plans.
What Did We Find?
Most public drug programs provide coverage for hospital-administered oncology medications listed on their formulary, with no cost to patients.
Between jurisdictions, there is variability in terms of public reimbursement of take-home oncology medications:
Some jurisdictions provide full coverage for take-home oncology medications if the medication is listed on their formulary and the patient meets prespecified clinical criteria, while other jurisdictions limit coverage to patients eligible for a specific drug plan.
In some cases, patients may receive varying levels of reimbursement depending on the drug plan they are enrolled in, and some may incur additional out-of-pocket costs.
Nearly all jurisdictions provide alternative pathways for the reimbursement of oncology medications not listed on their formulary.
Key differences between jurisdictions include how supportive medications are defined, the availability of programs covering high-cost treatments, and if and how CAR T-cell therapy is reimbursed.
What Does It Mean?
While most jurisdictions provide access to oncology medications delivered in hospital settings at no cost to patients, coverage for take-home medications is often dependent on specific eligibility criteria, income thresholds, patient age, and the availability of private insurance.
There may be opportunities for future alignment of oncology medication funding policies across public drug plans in Canada, including alignment of definitions for hospital-administered, take-home, and supportive care
Canada has an opportunity to learn from best practices in other jurisdictions to streamline reimbursement pathways and provide earlier, equitable access to new therapies for a greater number of patients, including specific access challenges associated with new dermatological treatments.
Maxwell Sauder, M. Ponzo· Canadian Dermatology Today· 0 citations
328
Background:
Supportive care medications are central to oncologic outcomes, yet unlike antineoplastic agents protected under Medicare Part D's six protected-class rules, supportive care agents remain subject to plan-level formulary and utilization management policies without equivalent federal protection. Th...
Yi-Xin Tang, Charles Jiang, Chuan Angel Lu et al.· JCO Oncology Practice· 0 citations
BACKGROUND
Off-label use of anticancer medicines is common. Investigator-initiated trials evaluating off-label indications often do not result in label expansion. Additionally, off-label use is often considered when approved treatments are lacking or exhausted. Such use may lead to uncertain efficacy and safety and pos...
H. Timmer, A. Huisman, H. Gelderblom et al.· ESMO Open· 0 citations
29
Background:
The 340b Drug Pricing Program, originally intended to support safety net providers, allows qualifying providers to purchase drugs at a discounted price. Eligibility criteria and participation have continued to expand; notably, hospitals can qualify if they have a “disproportionate share” of Medic...
N. Galanter, Ziad Zakaria, Akriti Mishra Meza et al.· JCO Oncology Practice· 0 citations
An insurance company denied coverage for an inflammatory bowel disease medication, stating that the lack of a pediatric Food and Drug Administration indication made that treatment experimental. This was legally permissible. The patient's pediatric gastroenterologist partnered with others to create a new state law that...
A. Al Dabbas, Matthew J. Giefer, John C. Carlson· Pediatrics· 0 citations
Background
Pediatric oncology patients are highly susceptible to medication errors, because chemotherapeutic agents are high-alert drugs with a narrow therapeutic index requiring individualized, weight-based dosing. Prospective intervention-based evidence from resource-limited settings is scarce. This study evaluated t...
Zahraa Samir Baqir, A. A. Rashid· Hospital Pharmacy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.